[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nuvation Bio Inc (NUVB)

Nuvation Bio Inc (NUVB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,699,749
  • Shares Outstanding, K 347,597
  • Annual Sales, $ 62,900 K
  • Annual Income, $ -204,630 K
  • EBIT $ -213 M
  • EBITDA $ -211 M
  • 60-Month Beta 1.60
  • Price/Sales 27.85
  • Price/Cash Flow N/A
  • Price/Book 5.71

Options Overview Details

View History
  • Implied Volatility 91.44% (-3.36%)
  • Historical Volatility 40.70%
  • IV Percentile 24%
  • IV Rank 7.84%
  • IV High 369.46% on 03/27/26
  • IV Low 67.79% on 07/22/25
  • Expected Move (DTE 18) 0.75 (14.75%)
  • Put/Call Vol Ratio 0.68
  • Today's Volume 247
  • Volume Avg (30-Day) 415
  • Put/Call OI Ratio 0.46
  • Today's Open Interest 28,890
  • Open Int (30-Day) 33,144
  • Expected Range 4.32 to 5.82

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $0.12
  • Number of Estimates 4
  • High Estimate $0.38
  • Low Estimate $0.01
  • Prior Year $-0.16
  • Growth Rate Est. (year over year) +175.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.05 +21.88%
on 03/30/26
5.29 -6.81%
on 04/22/26
+0.68 (+16.00%)
since 03/27/26
3-Month
4.05 +21.88%
on 03/30/26
6.22 -20.74%
on 02/05/26
-0.68 (-12.12%)
since 01/27/26
52-Week
1.57 +214.01%
on 06/16/25
9.75 -49.44%
on 12/22/25
+2.80 (+131.46%)
since 04/25/25

Most Recent Stories

More News
Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers

Guidelines include the next-generation targeted therapy as a systemic option for patients with ROS1-positive non-small cell lung cancer with brain metastases

NUVB : 4.79 (-2.04%)
Nuvation Bio Announces IBTROZI® (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at AACR 2026

  Analysis of longer-term pooled data from TRUST-I and TRUST-II demonstrated nearly 50 months median duration of response and 46.1 months median progression-free survival in TKI-naïve patients

NUVB : 4.79 (-2.04%)
Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026

NEW YORK , April 20, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will...

NUVB : 4.79 (-2.04%)
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency

The Marketing Authorisation Application (MAA) has been validated and accepted for full approval consideration with a standard review timeline

NUVB : 4.79 (-2.04%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB

NEW YORK , March 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nuvation Bio Inc. ("Nuvation" or the "Company") (NYSE: NUVB). Such investors are advised...

NUVB : 4.79 (-2.04%)
NUVB Investors Have Opportunity to Join Nuvation Bio Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Nuvation Bio Inc. (“NUVB” or “the Company”) (NYSE:...

NUVB : 4.79 (-2.04%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB

NEW YORK , March 19, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nuvation Bio Inc. ("Nuvation" or the "Company") (NYSE: NUVB).  Such investors are advised...

NUVB : 4.79 (-2.04%)
Nuvation Bio to Present Pivotal IBTROZI® (Taletrectinib) Data in TKI-Naïve and TKI-Pretreated Patients with Advanced ROS1-Positive Non-Small Cell Lung Cancer at AACR 2026

Clinical data demonstrate IBTROZI's unprecedented durability in TKI-naïve advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC), with median Duration of Response (DOR) now increased to...

NUVB : 4.79 (-2.04%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB

NEW YORK , March 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nuvation Bio Inc. ("Nuvation" or the "Company") (NYSE: NUVB).  Such investors are advised...

NUVB : 4.79 (-2.04%)
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm

NEW YORK , March 6, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Nuvation Bio Inc. (NYSE: NUVB) ...

NUVB : 4.79 (-2.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Nuvation Bio Inc. is a biopharmaceutical company. It engages in developing differentiated and novel therapeutic candidates for unmet needs in oncology. Nuvation Bio Inc., formerly known as Panacea Acquisition Corp., is based in NEW YORK.

See More

Key Turning Points

3rd Resistance Point 5.48
2nd Resistance Point 5.30
1st Resistance Point 5.10
Last Price 4.79
1st Support Level 4.72
2nd Support Level 4.54
3rd Support Level 4.34

See More

52-Week High 9.75
Fibonacci 61.8% 6.63
Fibonacci 50% 5.66
Last Price 4.79
Fibonacci 38.2% 4.69
52-Week Low 1.57

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.